PARION SCIENCES, INC.

Company Information
Address 2525 MERIDIAN PKY, STE 260
DURHAM, NC, 27713-2261


Information

DUNS: 096851774

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Novel Mucolytic Agents

    Amount: $319,012.00

    DESCRIPTION (provided by applicant): Mucus transport is the fundamental defense of the airways against inhaled particulates/infectious agents. Abnormalities in the mucus transport system characterize ...

    SBIRPhase I2013Department of Health and Human Services
  2. Hypertonic Saline for Cystic Fibrosis

    Amount: $1,509,420.00

    DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, ...

    SBIRPhase II2013Department of Health and Human Services
  3. Hypertonic Saline for Cystic Fibrosis

    Amount: $244,797.00

    DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, ...

    SBIRPhase I2011Department of Health and Human Services
  4. The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

    Amount: $1,059,726.00

    DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial dis ...

    SBIRPhase II2011Department of Health and Human Services
  5. The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

    Amount: $159,264.00

    DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial dis ...

    SBIRPhase I2010Department of Health and Human Services
  6. PHARMACOTHERAPRY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

    Amount: $379,296.00

    DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disease characterized by lymphocyte- mediated destruction of exocrine glands and internal organ involv ...

    SBIRPhase II2009Department of Health and Human Services
  7. DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

    Amount: $983,544.00

    DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary c ...

    SBIRPhase II2006Department of Health and Human Services
  8. PHARMACOTHERAPY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

    Amount: $489,999.00

    DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disorder characterized by lymphocyte-mediated destruction ofOverall, this application was found to hav ...

    SBIRPhase I2005Department of Health and Human Services
  9. DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

    Amount: $364,501.00

    DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary c ...

    SBIRPhase I2005Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government